Xifaxan is prescribed to treat traveler’s diarrhea caused by specific strains of E. coli, irritable bowel syndrome with diarrhea (IBS-D), and to prevent recurring episodes of hepatic encephalopathy.

Xifaxan, a brand-name antibiotic, may cause side effects like headaches, nausea, and elevated liver enzymes, depending on the condition being treated. Serious side effects may include diarrhea from ...

Xifaxan (rifaximin) is a prescription oral tablet that’s used to treat some types of diarrhea. It’s also used to lower certain risks in adults with specific liver problems. Xifaxan contains the active ...

Xifaxan (rifaximin) is a brand-name drug prescribed for irritable bowel syndrome with diarrhea (IBS-D), traveler’s diarrhea, and hepatic encephalopathy (HE). The drug’s dosage varies depending on a ...

Valeant Pharmaceuticals let loose its anthropomorphized, antsy “Gut Guy” during the third quarter of the 2016 Super Bowl. This ad for diarrhea drug Xifaxan is already making a splash: You can see the ...

Ms. Logan continued by stating, “ We also have comprehensive coverage for our XIFAXAN ® (rifaximin) tablets 200 mg product, which includes nine Orange Book listed patents, the latest of which expires ...

Bausch Health, after waylaying other copycats of its irritable bowel syndrome diarrhea (IBS-D) drug Xifaxan, has been dealt a blow in court. The court order potentially creates an opening for Norwich ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

LAVAL, Quebec, May 6, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"), ...

There was a lot of weirdness on the conference call that Valeant Pharmaceuticals held on Tuesday. Analysts were combative, and there was some confusion about how much cash the company's holding. It ...

A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...

Bausch Health, along with its gastroenterology business, Salix Pharmaceuticals, has filed a lawsuit in the United States District Court for the District of New Jersey against Amneal Pharmaceuticals of ...